Top

Published in:

Open Access 01-12-2014 | Research

Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer

Authors: Mounira El Demery, Gaiané Demirdjian-Sarkissian, Simon Thezenas, William Jacot, Yassine Laghzali, Bruno Darbouret, Stéphane Culine, Xavier Rebillard, Pierre-Jean Lamy

Published in: Clinical and Translational Medicine | Issue 1/2014

Abstract

Background

Urine markers have been studied extensively but there is a lack of blood prognostic markers in bladder cancer. MMP-7 is produced by stromal cells and by tumor cells and is overexpressed in a variety of epithelial and mesenchymal tumors. In this study, we assessed with an immunoassay we developed, the prognostic value of serum MMP-7 in a series of patients with advanced bladder cancer.

Methods

Serum samples were collected from 56 patients with advanced bladder cancer who were treated at the Montpellier Cancer Institute between March 2003 and December 2004. MMP-7 was quantified in serum samples by using a homogeneous sandwich fluoroimmunoassay we developed based on the time resolved amplified cryptate emission (TRACE) technology.

Results

The median overall survival of the study population was 2.2 years (95% CI, 1.4 to 3.0) with 1- and 5-year survival rates of 73% (95% CI, 59% to 82%) and 25% (95% CI, 14% to 37%), respectively. High MMP-7 serum levels were associated with poor survival. Using a cut-off value of 11.5 ng/mL, the median overall survival was 3.0 years (95% CI, 1.5 to 5.1) for patients with MMP-7 serum level <11.5 ng/mL and 1.3 years (95% CI, 0.8 to 2.5) for patients with serum level ≥11.5 ng/mL. Multivariate analysis identified high MMP-7 serum concentration as an independent prognostic factor for survival in patients with advanced bladder cancer (R = 2.1, 95% CI, 1.1 to 4.4).

Conclusions

Our results show that the MMP-7 serum concentration is an independent prognostic factor in patients with locally advanced and or metastatic bladder cancer.

Available only for authorised users

Grosclaude P, Velten M, Daubisse-Marliac L: Incidence of urogenital Tumors. Binder-Foucard F, Belot A, Delafosse P, et al. Estimation nationale de l’incidence et de la mortalité par cancer en France entre 1980 et 2012. Tumeurs solides. Saint-Maurice (Fra): Institut de veille sanitaire 2013.

Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008, 54: 303–314. 10.1016/j.eururo.2008.04.051CrossRefPubMed

Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49: 466–465. discussion 475–467 discussion 475-467 10.1016/j.eururo.2005.12.031CrossRefPubMed

Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP: Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006, 176: 2414–2422. discussion 2422 discussion 2422 10.1016/j.juro.2006.08.004CrossRefPubMed

Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg MP, Lerner SP: Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006, 176: 1354–1361. discussion 1361–1352 discussion 1361-1352 10.1016/j.juro.2006.06.025CrossRefPubMed

Szarvas T, Vom Dorp F, Ergun S, Rubben H: Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat Rev Urol 2011, 8: 241–254. 10.1038/nrurol.2011.44CrossRefPubMed

Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM: Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys 2002, 408: 155–161. 10.1016/S0003-9861(02)00525-8CrossRefPubMed

Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Kim SW, Song SK, Kim JH, Kim JR: Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF-induced in vitro invasion in human stomach cancer cells. Eur Surg Res 2007, 39: 208–215. 10.1159/000101452CrossRefPubMed

Ito TK, Ishii G, Saito S, Yano K, Hoshino A, Suzuki T, Ochiai A: Degradation of soluble VEGF receptor-1 by MMP-7 allows VEGF access to endothelial cells. Blood 2009, 113: 2363–2369. 10.1182/blood-2008-08-172742CrossRefPubMed

10.

Cornelius LA, Nehring LC, Harding E, Bolanowski M, Welgus HG, Kobayashi DK, Pierce RA, Shapiro SD: Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998, 161: 6845–6852.PubMed

11.

Shiomi T, Okada Y: MT1-MMP and MMP-7 in invasion and metastasis of human cancers. Cancer Metastasis Rev 2003, 22: 145–152. 10.1023/A:1023039230052CrossRefPubMed

12.

Jones LE, Humphreys MJ, Campbell F, Neoptolemos JP, Boyd MT: Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res 2004, 10: 2832–2845. 10.1158/1078-0432.CCR-1157-03CrossRefPubMed

13.

Miyata Y, Iwata T, Ohba K, Kanda S, Nishikido M, Kanetake H: Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis. Clin Cancer Res 2006, 12: 6998–7003. 10.1158/1078-0432.CCR-06-1626CrossRefPubMed

14.

Yamamoto H, Iku S, Adachi Y, Imsumran A, Taniguchi H, Nosho K, Min Y, Horiuchi S, Yoshida M, Itoh F, Imai K: Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J Pathol 2003, 199: 176–184. 10.1002/path.1277CrossRefPubMed

15.

Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, Marmol M, Gallardo E, Maria Auge J, Longaron R, Martinez-Fernandez A, Molina R, Castells A, Gascon P: Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer 2007, 121: 1066–1071. 10.1002/ijc.22799CrossRefPubMed

16.

Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Jung K: Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas. Cancer Sci 2008, 99: 1188–1194. 10.1111/j.1349-7006.2008.00802.xCrossRefPubMed

17.

Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellstrom I, Hellstrom KE, Urban N: Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol 2012, 125: 65–69. 10.1016/j.ygyno.2011.11.050PubMedCentralCrossRefPubMed

18.

Sarkissian G, Fergelot P, Lamy PJ, Patard JJ, Culine S, Jouin P, Rioux-Leclercq N, Darbouret B: Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin Chem 2008, 54: 574–581. 10.1373/clinchem.2007.090837CrossRefPubMed

19.

Szarvas T, Singer BB, Becker M, Vom Dorp F, Jager T, Szendroi A, Riesz P, Romics I, Rubben H, Ergun S: Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. BJU Int 2010, 107: 1069–1073. 10.1111/j.1464-410X.2010.09625.xCrossRefPubMed

20.

Szarvas T, Jager T, Becker M, Tschirdewahn S, Niedworok C, Kovalszky I, Rubben H, Ergun S, Vom Dorp F: Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancer. Pathol Oncol Res 2011, 17: 325–332. 10.1007/s12253-010-9320-4CrossRefPubMed

21.

Svatek RS, Shah JB, Xing J, Chang D, Lin J, McConkey DJ, Wu X, Dinney CP: A multiplexed, particle-based flow cytometric assay identified plasma matrix metalloproteinase-7 to be associated with cancer-related death among patients with bladder cancer. Cancer 2010, 116: 4513–4519. 10.1002/cncr.25401CrossRefPubMed

22.

Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999, 17: 3173–3181.PubMed

23.

Szarvas T, Becker M, Vom Dorp F, Gethmann C, Totsch M, Bankfalvi A, Schmid KW, Romics I, Rubben H, Ergun S: Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci 2010, 101: 1300–1308. 10.1111/j.1349-7006.2010.01506.xCrossRefPubMed

Title: Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer
Authors: Mounira El Demery
Gaiané Demirdjian-Sarkissian
Simon Thezenas
William Jacot
Yassine Laghzali
Bruno Darbouret
Stéphane Culine
Xavier Rebillard
Pierre-Jean Lamy
Publication date: 01-12-2014
Publisher: Springer Berlin Heidelberg
Published in: Clinical and Translational Medicine / Issue 1/2014
Electronic ISSN: 2001-1326
DOI: https://doi.org/10.1186/s40169-014-0031-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Transcriptional factor snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma

Clinical significance of epithelial-mesenchymal transition

Translational medicine as a new clinical tool and application which improves metabolic diseases: perspectives from 2012 Sino-American symposium on clinical and translational medicine

Lung flute improves symptoms and health status in COPD with chronic bronchitis: A 26 week randomized controlled trial

Application of clinical proteomics in acute respiratory distress syndrome

Possible mechanism and clinical potentials of allostery